613678-03-8

Usage

Uses

Used in Pharmaceutical Development:
(6-aMinopyridin-2-yl)(1-Methylpiperidin-4-yl)Methanone is used as a precursor in pharmaceutical development for its potential to target specific biological pathways. The presence of the aminopyridine group may contribute to its interaction with biological systems, making it a candidate for the creation of drugs that could address various medical conditions.
Used in Organic Synthesis:
In the field of organic synthesis, (6-aMinopyridin-2-yl)(1-Methylpiperidin-4-yl)Methanone is utilized as a key intermediate. Its unique structure allows it to participate in a variety of chemical reactions, facilitating the synthesis of more complex organic compounds.
Used in Medicinal Chemistry:
(6-aMinopyridin-2-yl)(1-Methylpiperidin-4-yl)Methanone is employed in medicinal chemistry as a structural component of potential drug molecules. Its ability to be modified and incorporated into larger molecules makes it valuable for the design of new pharmaceutical agents.
Note: Since the provided materials do not specify particular applications or industries for (6-aMinopyridin-2-yl)(1-Methylpiperidin-4-yl)Methanone, the uses listed are general and based on the potential of the compound as described. Further research would be required to identify specific applications in various industries.

Upstream product

• 613678-08-3 (6-bromopyridin-2-yl)(1-methylpiperidin-4-yl)methanone 
• 221087-47-4 N-(6-bromopyridin-2-yl)-2,2-dimethylpropanamide 
• 626-05-1 2,6-Dibromopyridine 
• 68947-43-3 1-methylpiperidine-4-carboxylic acid 
• 19798-81-3 2-Amino-6-bromopyridine 
• 71985-80-3 1-methylpiperidine-4-carboxylic acid hydrochloride 
• 613678-14-1 (1-methyl-4-piperidyl)pyrrolidin-1-ylmethanone 
• 103640-16-0 1-methylpiperidine-4-carboxylic acid diethylamide 
• 225112-16-3 6-Chloro-2-pyridyl 1-methyl-4-piperidinyl ketone 
• 215950-19-9 1-methyl-piperidine-4-carboxylic acid methoxy-methyl-amide 
• 109-09-1 2-chloropyridine 

Downstream Products

• 439239-90-4 Lasmiditan 
• 613677-28-4 2,4,6-trifluoro-N-[6-(1-methylpiperidin-4-ylcarbonyl)-pyridin-2-yl]benzamide hydrochloride 

Relevant academic research and scientific papers

Method for preparing 2 - amino -6 - (piperi -4 - acyl) pyridine derivative

The invention belongs to the technical field of drug synthesis, and particularly relates to a method for preparing 2 - amino -6 - (piperi -4 - acyl) pyridine derivatives. The ammonium salt and the alkali are adopted as raw materials, the ammonia gas in the prior art is replaced, and the danger of high-temperature high-pressure operation is avoided. The reaction condition is mild, the operation process is simple and convenient, the production cost is low, and the product has high purity and yield.

2,2-DIMETHYL-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL]-PROPIONAMIDE, METHOD FOR PREPARING (6-AMINO-PYRIDIN-2-YL)-(1-METHYL-PIPERIDIN-4-YL)-METHANONE USING SAID COMPOUND, AND USE OF SAID COMPOUND IN THE PREPARATION OF LASMIDITAN

The present invention relates to a new intermediate, (2,2-dimethyl-N-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-propanamide) useful in the synthesis of lasmiditan, to a method for obtaining same, to the use of said intermediate for preparing lasmiditan, to a method for preparing lasmiditan making use of said intermediate, and to a method for preparing an intermediate ((6-amino-pyridin-2-yl)-(1-methyl-piperidin-4-yl)-methanone) from (2,2-dimethyl-N-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-propanamide).

Pyridylpiperidine derivative and application thereof

The invention discloses a pyridylpiperidine derivative and application thereof, and particularly relates to a novel pyridylpiperidine derivative and a pharmaceutical composition containing the compound, which can be used for activating a 5-HT1F receptor.

Synthesis method of 2-amino-6-(1-alkyl piperidine-4-carbonyl)pyridine compound

The invention relates to a synthesis method of a 2-amino-6-(1-alkyl piperidine-4-carbonyl)pyridine compound, and provides a method for synthesizing a 5-HT1f agonist pyridine carbonyl piperidine precursor (general formula 1), wherein an N-(6-bromopyridine-2-yl)amide compound (general formula 2) is converted into a corresponding metal reagent by using an organic metal reagent (RM), and is continuously subjected to an addition reaction with 1-alkyl piperidine-4-formamide or Weinreb's formamide thereof or formate (general formula 3), hydrolyzing is performed, and the protecting group of amide is removed to obtain the 2-amino-6-(1-alkyl piperidine-4-carbonyl) pyridine compound (general formula 1).

Discovery of selective N-[3-(1-methyl-piperidine-4-carbonyl)-phenyl]-benzamide-based 5-HT1F receptor agonists: Evolution from bicyclic to monocyclic cores

Preclinical experiments and clinical observations suggest the potential effectiveness of selective 5-HT1F receptor agonists in migraine. Identifying compounds with enhanced selectivity is crucial to assess its therapeutic value. Replacement of the indole nucleus in 2 (LY334370) with a monocyclic phenyl ketone moiety generated potent and more selective 5-HT1F receptor agonists. Focused SAR studies around this central phenyl ring demonstrated that the electrostatic and steric interactions of the substituent with both the amide CONH group and the ketone C=O group play pivotal roles in affecting the adopted conformation and thus the 5-HT1F receptor selectivity. Computational studies confirmed the observed results and provide a useful tool in the understanding of the conformational requirements for 5-HT1F receptor agonist activity and selectivity. Through this effort, the 2-F-phenyl and N-2-pyridyl series were also identified as potent and selective 5-HT1F receptor agonists.

PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS

The present invention relates to compounds of formula I:or pharmaceutically acceptable acid addition salts thereof, where;R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II II;R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl;R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.